These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20035703)

  • 1. [Regulatory consequences for the use of monoclonal antibodies].
    Lackner F; Behr-Gross ME
    Med Sci (Paris); 2009 Dec; 25(12):1183-8. PubMed ID: 20035703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies--regulatory challenges.
    Schneider CK
    Curr Pharm Biotechnol; 2008 Dec; 9(6):431-8. PubMed ID: 19075683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Tysabri survived.
    Huggett B
    Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Biosimilar' drugs poised to penetrate market.
    Ledford H
    Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
    [No Abstract]   [Full Text] [Related]  

  • 7. Promising drug is victim of bad business.
    Dove A
    Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
    [No Abstract]   [Full Text] [Related]  

  • 8. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibodies to watch in 2020.
    Kaplon H; Muralidharan M; Schneider Z; Reichert JM
    MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarity trials.
    Nat Biotechnol; 2011 Jan; 29(1):1. PubMed ID: 21221076
    [No Abstract]   [Full Text] [Related]  

  • 11. Avastin hearing leads to more uncertainty over drug's future.
    Goozner M
    J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
    [No Abstract]   [Full Text] [Related]  

  • 12. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic drugs advisory committee recommends withdrawing approval for bevacizumab use in breast cancer treatment.
    Future Oncol; 2010 Sep; 6(9):1374. PubMed ID: 20931736
    [No Abstract]   [Full Text] [Related]  

  • 14. How to evaluate the benefit-risk profile of newly marketed drugs.
    Naldi L
    Ann Dermatol Venereol; 2010 Apr; 137(4):264-6, 261-3. PubMed ID: 20417357
    [No Abstract]   [Full Text] [Related]  

  • 15. Changing end points in breast-cancer drug approval--the Avastin story.
    D'Agostino RB
    N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
    [No Abstract]   [Full Text] [Related]  

  • 16. Reputation and precedent in the bevacizumab decision.
    Carpenter D; Kesselheim AS; Joffe S
    N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
    [No Abstract]   [Full Text] [Related]  

  • 17. Changing innovation into a registered product: From concept to regulatory approval.
    Rhodes L
    Theriogenology; 2018 May; 112():75-81. PubMed ID: 28716338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
    Liberti L; Breckenridge A; Eichler HG; Peterson R; McAuslane N; Walker S
    Clin Pharmacol Ther; 2010 Jan; 87(1):27-31. PubMed ID: 20019699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.